New pill for tough lymphomas shows early promise, but trial stopped short

NCT ID NCT03779113

Terminated Disease control Sponsor: Hutchmed Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an oral drug called HMPL-523 in 69 people with lymphoma that had returned or stopped responding to other treatments. The main goals were to check safety and find the right dose. The study was terminated early, so we have limited information on how well it works, but researchers did collect data on side effects and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HMPL-523 (an oral drug that targets a protein called Syk, involved in cancer cell growth)

What this could lead to

If successful, HMPL-523 could offer a new treatment option for people with lymphoma who have run out of standard therapies.

What could go wrong

This was a very early (phase 1) trial that was terminated, so we don't know if the drug works well. It may cause side effects like low blood counts or other toxicities.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia Hodgkins lymphoma lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON HODGKIN LYMPHOMA

Contacts and locations

Show contact details

Locations

Aarhus University Hospital

Aarhus, Denmark
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

Bergamo, Bergamo, 24127, Italy
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)

Monza, Italy
CHU Clermont Ferrand - Hôpital d'Estaing

Clermont-Ferrand, France
CHU Poitiers - Hôpital la Milétrie

Poitiers, France
Clinical Research Alliance

New Hyde Park, New York, 11042, United States
Fundacion Jimenez Diaz

Madrid, Spain
Groupe Hospitalier Pitie-Salpetriere

Paris, France
Helsingin yliopistollinen keskussairaala

Helsinki, 00029, Finland
Hospital Universitari Vall d'Hebron

Barcelona, Spain
Hospital Universitario Infanta Leonor

Madrid, Spain
Hospital Universitario Quironsalud Madrid

Madrid, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
Hospital Universitario Virgen Macarena

Seville, Spain
Hospital Universitario Virgen del Rocio

Seville, Spain
Hôpital Henri Mondor

Créteil, France
ICO Badalona - Hospital Universitari Germans Trias i Pujol

Barcelona, Spain
Innovative Clinical Research Institute

Downey, California, 90241, United States
Institut Català d'Oncologia

Barcelona, Spain
KO-MED Centra Kliniczne

Biała Podlaska, Poland
Leo Jenkins Cancer Center/ECU School of Medicine

Greenville, North Carolina, 27834, United States
MD Anderson Cancer Centre

Madrid, Spain
Nasz Lekarz Przychodnie Medyczne

Torun, Poland
Ospedale San Raffaele

Milan, Milano, 20132, Italy
Pacific Cancer Medical Center, Inc.

Anaheim, California, 92801, United States
Renovatio Clinical

The Woodlands, Texas, 77380, United States
Summit Medical Group

Florham Park, New Jersey, 07932, United States
Tampereen yliopistollinen sairaala

Tampere, 33520, Finland
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego

Wroclaw, 50566, Poland
Uniwersyteckie Centrum Kliniczne

Gdansk, Poland
Ventura County Hematology-Oncology Specialists

Oxnard, California, 93030, United States